Acquisition of Patents and Intangibles (Tables)

9 Months Ended

Feb. 29, 2020

Summary of the Net Purchase Price and Allocation to the Acquired Assets

A summary of the net purchase price and allocation to the acquired assets of ProstaGene is as follows:

	ProstaGene, LLC
CytoDyn Inc. Equity	$	11,558,000
Acquisition Expenses		741,297
Release of Deferred Tax Asset		2,826,919
Total Cost of Acquisition	$	15,126,216
Intangible assets	$	15,126,216
Other		—
Allocation of Acquisition Costs	$	15,126,216

Intangible Assets Activity

The following presents intangible assets activity:

	February 29, 2020			May 31, 2019
Gross carrying amounts	$	3,500,000		$	3,500,000
Development of new Company website	$	19,552		$	19,552
Intangible asset acquisition:
ProstaGene, LLC		15,126,216			15,126,216
Accumulated amortization		(4,692,813	)		(3,170,314	)
Total amortizable intangible assets, net	$	13,952,955		$	15,475,454
Patents currently not amortized	$	—		$	—
Carrying value of intangibles, net	$	13,952,955		$	15,475,454